- Trials with a EudraCT protocol (9)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
9 result(s) found for: End plate potential.
Displaying page 1 of 1.
EudraCT Number: 2017-000748-16 | Sponsor Protocol Number: MT-2-01 | Start Date*: 2017-09-14 |
Sponsor Name:Minoryx Therapeutics S.L. | ||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL, MULTICENTER STUDY WITH OPEN-LABEL TREATMENT EXTENSION TO ASSESS THE EFFECT OF MIN-102 ON THE PROGRESSION OF ADRENOMYELONEUROPATHY IN M... | ||
Medical condition: ADRENOMYELONEUROPATHY IN MALE PATIENTS WITH X-LINKED ADRENOLEUKODYSTROPHY | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) ES (Ongoing) NL (Completed) PL (Prematurely Ended) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004530-14 | Sponsor Protocol Number: 1199-0337 | Start Date*: 2019-10-15 | |||||||||||
Sponsor Name:Boehringer Ingelheim España, S.A. | |||||||||||||
Full Title: A double blind, randomised, placebo-controlled trial to evaluate the dose-exposure and safety of nintedanib per os on top of standard of care for 24 weeks, followed by open label treatment with nin... | |||||||||||||
Medical condition: Interstitial Lung Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) PT (Completed) FI (Completed) NO (Completed) DK (Completed) FR (Completed) CZ (Completed) PL (Completed) GR (Completed) HU (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002855-40 | Sponsor Protocol Number: REN001-201 | Start Date*: 2021-04-15 | |||||||||||
Sponsor Name:Reneo Pharma Ltd. | |||||||||||||
Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 24 WEEKS TREATMENT WITH REN001 IN PATIENTS WITH PRIMARY MITOCHONDRIAL MYOPATHY (PMM) | |||||||||||||
Medical condition: Primary Mitochondrial Myopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) CZ (Completed) DK (Completed) HU (Completed) BE (Completed) IT (Completed) ES (Ongoing) NL (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004328-12 | Sponsor Protocol Number: Europe | Start Date*: 2015-01-23 | |||||||||||
Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH | |||||||||||||
Full Title: Prospective validation of a predictive model of response to romiplostim in patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia - the EUROPE-trial | |||||||||||||
Medical condition: Patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Ongoing) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011125-14 | Sponsor Protocol Number: RV4104A-2008-548 | Start Date*: 2009-07-06 | |||||||||||
Sponsor Name:Pierre Fabre Dermatologie | |||||||||||||
Full Title: A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solutio... | |||||||||||||
Medical condition: Patients suffering from distal-lateral or lateral subungual onychomycosis of one great toenail (the target nail) without matrix involvement | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000850-36 | Sponsor Protocol Number: 201600136 | Start Date*: 2017-05-01 |
Sponsor Name:Archivel Farma S.L. | ||
Full Title: Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients with Multi-Drug Resistant Tuberculos... | ||
Medical condition: The medical condition to be investigated is culture-confirmed Multidrug-resistant tuberculosis, i.e. tuberculosis resistant to the two first-line drugs Rifampicin and Isoniazid | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002096-17 | Sponsor Protocol Number: EORTC-1762-STBSG | Start Date*: 2020-04-21 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: Reduced dose-density of denosumab for maintenance therapy of unresectable giant cell tumor of bone: a multicenter phase II study "REDUCE" | |||||||||||||
Medical condition: Giant cell tumor of bone | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DK (Completed) ES (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002418-23 | Sponsor Protocol Number: W0027-10 | Start Date*: 2008-12-17 | ||||||||||||||||
Sponsor Name:Stiefel Laboratories Inc. | ||||||||||||||||||
Full Title: A phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in subjects with distal su... | ||||||||||||||||||
Medical condition: Distal subungual onychomycosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IS (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003471-34 | Sponsor Protocol Number: REN001-202 | Start Date*: 2022-04-19 | |||||||||||
Sponsor Name:Reneo Pharma Ltd. | |||||||||||||
Full Title: AN OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF REN001 IN SUBJECTS WITH PRIMARY MITOCHONDRIAL MYOPATHY (PMM) | |||||||||||||
Medical condition: Primary Mitochondrial Myopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) BE (Completed) HU (Prematurely Ended) NL (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
